A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

New England Journal of Medicine - United States
doi 10.1056/nejmoa044397
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

ACCLAIM: A Randomized Trial of Abatacept (CTLA4-Ig) for Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis
Neurology
2016English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Safety and Acceptability of Clozapine and Risperidone in Progressive Multiple Sclerosis: A Phase 1, Randomized, Blinded, Placebo-Controlled Trial

2020English

Short-Term Interval Aerobic Exercise Training Does Not Improve Memory Functioning in Relapsing-Remitting Multiple Sclerosis—a Randomized Controlled Trial

PeerJ
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgriculturalNeuroscience
2018English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Effect of Natalizumab on Disease Progression in Secondary Progressive Multiple Sclerosis (ASCEND): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial With an Open-Label Extension

The Lancet Neurology
Neurology
2018English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy